Paleo Raises $2.3M for Animal-Free Heme
Paleo raised new funding to support regulatory work for precision-fermented proteins used in plant-based meat and seafood.
Alternative protein is quieter than during the hype cycle, but enabling ingredients are still attracting capital.
What happened
Belgian biotech Paleo raised about €2M, roughly $2.3M, to support US regulatory approval for precision-fermented myoglobin proteins.
The company’s proteins are designed to improve the taste, colour and nutritional profile of plant-based meat and seafood. Rather than selling a finished consumer product, Paleo is working on an ingredient layer for other food companies.
Why it matters
Plant-based meat has struggled with repeat purchasing, taste expectations and investor fatigue. That makes ingredient innovation more important. If enabling technologies can improve the sensory experience, the category may become more competitive again.
Paleo’s funding is not large, but it points to a more disciplined alternative-protein market: less splashy branding, more focus on regulatory approval, formulation and measurable product improvement.
The bigger picture
Food and biotech are increasingly overlapping. Precision fermentation can create ingredients that are difficult or inefficient to source from animals. The next stage for the sector will depend on cost, regulation and whether better ingredients can translate into products consumers actually want to buy again.